Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (51-60 of 229) with videos related to

Pageof 23
Sort By:
Journal of Health Services Research & Policy|January 25, 2007
The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysmHelen Campbell, Andrew Briggs, Martin Buxton, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 5, 2013
The "hazards" of extrapolating survival curvesCharlotte Davies, Andrew Briggs, Paula Lorgelly, et al.
Plos One|March 10, 2015
Hospital expenditure at the end-of-life: what are the impacts of health status and health risks?Claudia Geue, Paula Lorgelly, James Lewsey, et al.
Pharmacoeconomics|November 6, 2022
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A TutorialNathan Green, Felicity Lamrock, Nichola Naylor, et al.
European Heart Journal|December 14, 2017
'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapiesLieven Annemans, Chris J Packard, Andrew Briggs, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 16, 2016
Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancerGabriel Tremblay, Christopher Livings, Lydia Crowe, et al.
Journal of Managed Care & Specialty Pharmacy|March 3, 2022
Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory settingNick Jovanoski, Andreas Kuznik, Ursula Becker, et al.
Journal of Patient-Reported Outcomes|January 13, 2021
The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial dataAndrew Briggs, Shuaib Nasser, Eva Hammerby, et al.
Journal of Medical Economics|July 30, 2019
A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trialKatherine Dick, Andrew Briggs, Robert Ohsfeldt, et al.
Transplantation|May 9, 2009
Acute rejection and chronic nephropathy: a systematic review of the literatureOlivia Wu, Adrian R Levy, Andrew Briggs, et al.
Pageof 23

Showing results (51-60 of 229) with videos related to

Sort By:
Pageof 23
Journal of Health Services Research & Policy|January 25, 2007
The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysmHelen Campbell, Andrew Briggs, Martin Buxton, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 5, 2013
The "hazards" of extrapolating survival curvesCharlotte Davies, Andrew Briggs, Paula Lorgelly, et al.
Plos One|March 10, 2015
Hospital expenditure at the end-of-life: what are the impacts of health status and health risks?Claudia Geue, Paula Lorgelly, James Lewsey, et al.
Pharmacoeconomics|November 6, 2022
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A TutorialNathan Green, Felicity Lamrock, Nichola Naylor, et al.
European Heart Journal|December 14, 2017
'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapiesLieven Annemans, Chris J Packard, Andrew Briggs, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 16, 2016
Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancerGabriel Tremblay, Christopher Livings, Lydia Crowe, et al.
Journal of Managed Care & Specialty Pharmacy|March 3, 2022
Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory settingNick Jovanoski, Andreas Kuznik, Ursula Becker, et al.
Journal of Patient-Reported Outcomes|January 13, 2021
The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial dataAndrew Briggs, Shuaib Nasser, Eva Hammerby, et al.
Journal of Medical Economics|July 30, 2019
A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trialKatherine Dick, Andrew Briggs, Robert Ohsfeldt, et al.
Transplantation|May 9, 2009
Acute rejection and chronic nephropathy: a systematic review of the literatureOlivia Wu, Adrian R Levy, Andrew Briggs, et al.
Pageof 23